For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Alpha Cognition Inc. (ACOG) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Alpha Cognition Inc. is a member of our Medical group, which includes 989 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the st ...

Alpha Cognition Inc. (ACOG) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ACOG's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross."There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer-term moving average ...

Alpha Cognition (NASDAQ: ACOG ) is an relatively unknown pharmaceutical company that just launched its first commercial product, Zunveyl (benzgalantamine), in March for the symptomatic treatment of mild-to-moderate Alzheimer’s disease (AD). After receiving FDA approval in July 2024, Alpha Cognition quietlyAnalyst’s Disclosure: I/we have a beneficial long position in the shares of ACOG either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions ...

Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.75 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 65.52%. A quarter ago, it was expected that this company would post a loss of $0.48 per share when it actually produced a loss of $0.51, delivering a surprise of -6.25%.Over the last four quarters, the company has sur ...

Alpha Cognition (ACOG) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Henry Du - Interim CFO, VP of Finance & AccountingMichael McFadden - Director & CEOLauren D'Angelo - COORaghuram Selvaraju - Managing Director, Healthcare Equity ResearchDave Storms - Director of Equity Research Conference Call Participants Michael Freeman - Equity Research Analyst - Healthcare Operator Greetings, and welcome to the AlphaCognition Earnings Call. At this time, all participants are in a listen only mode ...

Alpha Cognition (ACOG) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Speaker0 Greetings, and welcome to the AlphaCognition Earnings Call. At this time, all participants are in a listen only mode. A brief question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Henry Du, AlphaCognition's Interim CFO. Thank you. You may begin. Speaker1 Thank you, Sachi. Good afternoon, everyone, and thank you for joining u ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-42403 Alpha Cognition Inc. (Exact Name of Registrant as Specified in its Charter) | British Columbia | N/A | | --- | --- | | (S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | Title of each class: | Trading Symbol | Name of each exchange on which registered: | | --- | --- | --- | | Common Shares, no par value | ACOG | The Nasdaq Sto ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-42403 Alpha Cognition Inc. (Exact Name of Registrant as Specified in its Charter) | British Columbia | N/A | | --- | --- | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-278997 Securities registered pursuant to Section 12(b) of the Act: None Indicate by checkmark whether the registrant (1) filed a ...